Lundbeck 
Welcome,         Profile    Billing    Logout  
 42 Products   82 Diseases  42 Products   77 Trials   4819 News 
156 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lu AF11167 / Lundbeck
2018-002708-15: Flexible-dose Long-term Extension Study of Lu AF11167 in Patients WithSchizophrenia With Prominent Negative Symptoms

Not yet recruiting
2
240
Europe, RoW
Lu AF11167 modified-release tablet, Modified-release tablet
H. Lundbeck A/S, H. Lundbeck A/S
schizophrenia with persistent prominent negative symptoms, schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
SCHIZO2: P1 / schizophrenia

Ongoing
1
0
RoW
Lu AF11167
Lundbeck
Schizophrenia
 
 
brexpiprazole / Generic mfg.
ACTRN12619001456145p: Does supplemental brexpiprazole affect sleep-wake and circadian parameters in youth with depressive syndromes?

Not yet recruiting
4
50
 
University of Sydney, Lundbeck Australia Pty Ltd
circadian parameters; depression
 
 
ACTRN12619001456145: Does supplemental brexpiprazole affect sleep-wake and circadian parameters in youth with depressive syndromes?

Terminated
4
50
 
University of Sydney, Lundbeck Australia Pty Ltd
circadian parameters, depression
 
 
NCT03526354: Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

Completed
4
50
US
Brexpiprazole, Study Medication, Treatment as Usual, Current Antipsychotic Treatment
University of Massachusetts, Worcester, Massachusetts General Hospital, University of North Carolina, Chapel Hill, Otsuka Pharmaceutical Co., Ltd., Augusta University
Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
02/24
02/24
NCT06580041: Precision Care for Major Depressive Disorder

Enrolling by invitation
4
150
US
Pramipexole, Methylphenidate, Phenelzine, Mindfulness-based Stress Sensitivity Therapy (MBSST), Complicated Grief Treatment (CGT), Care as usual (CAU) plan
University of California, San Francisco
Major Depressive Disorder, Depression, Depressive Disorder, Major
09/29
09/29
CAN-BIND-17, NCT05017311: Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Recruiting
4
400
Canada
Escitalopram, Cipralex, Brexpiprazole, Rexulti
Nova Scotia Health Authority, Unity Health Toronto, Centre for Addiction and Mental Health, McMaster University, Queen's University, University of Ottawa, University of British Columbia, University of Calgary, McGill University, Dalhousie University, University of Michigan, Simon Fraser University
Major Depressive Disorder
12/28
04/29
NCT03538691 / 2018-000601-22: A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Completed
3
1149
US
Brexpiprazole, OPC-34712, Rexulti, Antidepressant therapy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
07/22
07/22
2018-002783-88: A 12-week, Multicenter, Active-treatment Extension Trial to check how safe, tolerable and effective Brexpiprazole is in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type

Not yet recruiting
3
250
Europe
Brexpiprazole, OPC-34712, Film-coated tablet, REXULTI®
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation Associated With Dementia of the Alzheimer's Type, Agitation in dementia due to Alzheimer's Disease, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04162522: Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study

Completed
3
1
Canada
Escitalopram, Cipralex, Brexpiprazole, Rexulti
University Health Network, Toronto, Unity Health Toronto, Baycrest, Centre for Addiction and Mental Health, McMaster University, Queen's University, University of Ottawa, University of British Columbia, University of Calgary, McGill University, Dalhousie University, University of Michigan, Simon Fraser University
Major Depressive Disorder
12/22
12/22
NCT03198078 / 2017-001447-12: Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Completed
3
316
US
Brexpiprazole (OPC-34712), Aripiprazole, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc., H. Lundbeck A/S
Schizophrenia
04/23
04/23
NCT04258839 / 2018-004899-35: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Completed
3
95
US
Brexpiprazole, OPC-34712, LuAF41156
Otsuka Pharmaceutical Development & Commercialization, Inc., H. Lundbeck A/S
Irritability Associated With Autism Spectrum Disorder
03/23
03/23
NCT04124614: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

Completed
3
450
US
Brexpiprazole, Rexulti, Sertraline, Zoloft, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Post Traumatic Stress Disorder
07/23
08/23
NCT04174170: Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder

Completed
3
591
US
Brexpiprazole, Rexulti, Sertraline, Zoloft, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Post Traumatic Stress Disorder
07/23
08/23
2018-004899-35: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Not yet recruiting
3
95
US
Rexulti, Tablet, Rexulti
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc.
Irritability Associated With Autism Spectrum Disorder, AutismAutism Spectrum DisorderASDIrritability, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2019-000723-40: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder ( Anchor )

Not yet recruiting
3
130
US
Rexulti, Tablet, Rexulti
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc.
Irritability Associated With Autism Spectrum Disorder (ASD), AutismIrritabilityAutism Spectrum DisorderASD, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT04569448: Brexpiprazole Treatment for Bipolar I Depression

Recruiting
3
58
Canada
Brexpiprazole
Douglas Mental Health University Institute, McMaster University, Jewish General Hospital
Bipolar Depression
02/25
02/25
NCT03238326 / 2017-001459-30: Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Active, not recruiting
3
295
Europe, US, RoW
Brexpiprazole, OPC-34712
Otsuka Pharmaceutical Development & Commercialization, Inc., H. Lundbeck A/S
Schizophrenia
06/25
08/25
NCT03620981: Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Completed
2/3
410
Japan
Brexpiprazole, Placebo
Otsuka Pharmaceutical Co., Ltd.
Agitation Associated With Dementia of the Alzheimer's Type
04/23
05/23
ACTRN12623001019695: Investigating Novel Pharmacological Treatments for Anorexia Nervosa - A Clinical Trial

Recruiting
2
100
 
Monash University, Monash University
Anorexia nervosa
 
 
2019-002813-20: A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Not yet recruiting
2
240
Europe
Brexpiprazole, OPC-34712, Tablet
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc.
Borderline Personality Disorder, Borderline Personality Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT04066192: Brexpiprazole in Alcohol Use Disorder

Recruiting
2
250
US
Brexpiprazole, Placebo
University of Colorado, Denver, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder
08/25
08/25
NCT05189977: A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

Terminated
1
34
US
Propranolol, Prazosin
Otsuka Pharmaceutical Development & Commercialization, Inc., Iqvia Pty Ltd
Post-traumatic Stress Disorder (PTSD)
08/23
08/23
RAISE, NCT04641780: "Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients () - A Post Marketing Surveillance Program"

Recruiting
N/A
300
RoW
Brexpiprazole, Rexulti
Otsuka Pharmaceutical, Inc., Philippines
Schizophrenia, Major Depressive Disorder
06/23
03/24
MainRexult, NCT05169268: Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia

Recruiting
N/A
10
RoW
ARIPiprazole Injection [Abilify], Abilify Maintena, Brexpiprazole, Rexulti
The University of Hong Kong
Schizophrenia and Related Disorders, Anxiety Depression
12/24
06/25
NCT06875986: REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)

Recruiting
N/A
200
Japan
Brexpiprazole (Rexulti)
Otsuka Pharmaceutical Co., Ltd.
Alzheimer Disease
09/27
09/28
ReSD, NCT05962216: Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders

Recruiting
N/A
40
RoW
Brexpiprazole, Rexulti
Dr. Albert Kar-Kin Chung, Otsuka Pharmaceutical Co., Ltd.
Psychosis, Depression
12/25
12/25
clazakizumab (CSL300) / CSL Behring
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Recruiting
2/3
2310
Europe, Canada, Japan, US, RoW
CSL300, Clazakizumab, Placebo
CSL Behring
Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
08/29
08/29
ACTRN12624000567527: A Phase II Trial to Evaluate the Safety and Efficacy of clazakizumab for the desensitisation of highly sensitized patients on the deceased donor kidney transplant waiting list

Not yet recruiting
2
10
 
Royal Melbourne Hospital, John Perrett Bequest
End stage kidney disease
 
 
2020-002476-13: A study to look at the safety and success of using Clazakizumab in patients who have kidney disease and COVID-19.

Ongoing
2
20
Europe
Clazakizumab, N/A, Solution for injection/infusion, Clazakizumab
Imperial College London, Vitaeris Bio
Patients with kidney disease who are hospitalised with COVID-19 infection with pulmonary involvement (i.e. consistent chest imaging abnormalities) and clinical deterioration (i.e increasing oxygen requirements or biochemical signs of hyperinflammation)., Patients with kidney disease or who are immunosuppressed, who also have a diagnosis of COVID19, which affects the lungs, requiring a hospital admission., Diseases [C] - Virus Diseases [C02]
 
 
NCT04494724: Clazakizumab vs. Placebo - COVID-19 Infection

Recruiting
2
60
US
Clazakizumab, Placebo
The Methodist Hospital System
COVID-19 Infection
12/20
07/21
NCT04363502: Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

Recruiting
2
30
US
Clazakizumab, engineered humanized mAb directed against the human cytokine IL-6, Placebo
Johns Hopkins University
Covid19
05/22
05/22
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Completed
2
395
US
MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
02/25
03/25
RIGHT, NCT05727384: Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The Study

Recruiting
2
60
US
Clazakizumab, Placebo
Anne B. Newman, CSL Behring
Inflammation, Frailty
01/26
06/26
NCT03380962: Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

Active, not recruiting
1/2
20
US
Clazakizumab, Anti-IL-6 monoclonal
Stanley Jordan, MD
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
08/25
08/25
NCT03380377: Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

Completed
1/2
10
US
Clazakizumab
Stanley Jordan, MD
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
04/24
04/24
Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
ACTRN12621001616864: An evaluation of the efficacy of eptinezumab in the inpatient management of status migrainosus in comparison to intravenous lignocaine in patients who have failed other therapies

Recruiting
4
40
 
Alfred Health , Alfred Hospital
Migraine
 
 
2021-003049-40: A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Estudio con eptinezumab en participantes con migraña y cefalea por abuso de medicamentos

Not yet recruiting
4
570
Europe
VYEPTI, ALD403, Concentrate for solution for infusion, VYEPTI
H. Lundbeck A/S, H. LUNDBECK A/S, H. Lundbeck A/S
Migraine and medication overuse headache Migraña y cefalea por abuso de medicamentos, Migraine and medication overuse headache Migraña y cefalea por abuso de medicamentos, Diseases [C] - Nervous System Diseases [C10]
 
 
EVEC, NCT05284019: Real World Effectiveness of Eptinezumab in Participants With Migraine

Terminated
4
32
US
Eptinezumab, Vyepti, Erenumab, Aimovig®, Onabotulinumtoxin-A, Fremanezumab, Ajovy®, Galcanezumab, Emgality®
H. Lundbeck A/S
Migraine
02/23
04/23
NCT05452239 / 2021-003049-40: A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

Completed
4
609
Europe, US, RoW
Eptinezumab, Placebo
H. Lundbeck A/S, H. Lundbeck A/S
Migraine, Medication Overuse Headache
10/24
03/25
NCT06701526: A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

Recruiting
4
150
US
Eptinezumab
H. Lundbeck A/S
Migraine
06/26
06/26
2020-001009-22: Interventional, randomized, double-blind, parallel-group, placebocontrolled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of chronic migraine Estudio intervencionista, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de eptinezumab IV en adolescentes (12-17 años) para el tratamiento preventivo de la migraña crónica

Not yet recruiting
3
285
Europe
Eptinezumab, [NA], Concentrate for solution for infusion, Vyepti
H. Lundbeck A/S, H. LUNDBECK A/S, H. Lundbeck A/S
Migraine Migraña, Migraine Migraña, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-001649-38: Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine Estudio de extensión a largo plazo, abierto (con enmascaramiento de la dosis), de eptinezumab en niños y adolescentes con migraña crónica o episódica

Not yet recruiting
3
645
Europe
Eptinezumab, [NA], Concentrate for solution for infusion, Vyepti
H. Lundbeck A/S, H. LUNDBECK A/S, H. Lundbeck A/S
Migraine Migraña, Migraine Migraña, Diseases [C] - Nervous System Diseases [C10]
 
 
ALLEVIATE, NCT04688775 / 2020-001969-37: Eptinezumab in Participants With Episodic Cluster Headache

Completed
3
231
Europe, Japan, US, RoW
Eptinezumab, Placebo
H. Lundbeck A/S
Cluster Headache, Episodic
06/23
10/23
CHRONICLE, NCT05064397 / 2020-001968-28: A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)

Completed
3
131
Europe, US
Eptinezumab, Vyepti
H. Lundbeck A/S
Chronic Cluster Headache
06/23
06/23
PROSPECT-2, NCT04965675 / 2020-001009-22: A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Recruiting
3
285
Europe, Canada, US, RoW
Eptinezumab, Vyepti, Placebo
H. Lundbeck A/S, H. Lundbeck A/S
Chronic Migraine in Children
02/26
03/26
NCT05064371: Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

Completed
3
160
Japan
Eptinezumab
H. Lundbeck A/S
Migraine
06/24
06/24
NCT06428838: Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context

Not yet recruiting
3
102
Canada
Eptinezumab, Standard of Care
Dr George Medvedev, H. Lundbeck A/S, Centre for Neurology Studies, Surrey Neuroplasticity Clinic Inc., Royal Columbian Hospital, Surrey Memorial Hospital
Migraine, Chronic Migraine
12/25
12/25
Sunrise, NCT04921384 / 2020-001657-42: Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

Completed
3
981
Europe, Japan, RoW
Placebo, Eptinezumab, Lu AG09221
H. Lundbeck A/S, H. Lundbeck A/S
Migraine
10/24
02/25
PROSPECT-1, NCT05897320: A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Recruiting
3
315
Europe, Canada, US, RoW
Eptinezumab, Placebo
H. Lundbeck A/S
Episodic Migraine
05/27
06/27
NCT05164172 / 2020-001649-38: A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Recruiting
3
600
Europe, Canada, US, RoW
Eptinezumab, Vyepti
H. Lundbeck A/S, H. Lundbeck A/S
Migraine
09/25
03/26
NCT05937152: A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy

Withdrawn
2
100
Europe, US
Eptinezumab, Placebo
Mayo Clinic
Diabetic Polyneuropathy
11/25
11/25
NCT04537429 / 2022-004102-29: A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

Completed
1
28
US
Eptinezumab
H. Lundbeck A/S, H. Lundbeck A/S
Migraine in Children, Migraine
10/22
08/23
2022-004102-29: A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

Not yet recruiting
1
32
US
VYEPTI, Concentrate for solution for infusion, VYEPTI
H. Lundbeck A/S, H. Lundbeck A/S
Migraine in children and adolescentsMigraine, Migraine in children and young peopleMigraine, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05635604: Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.

Completed
N/A
38
Europe
Eptinezumab, PACAP-38
Danish Headache Center
Migraine
08/23
08/23
TACHIS, NCT06409845: Effectiveness and Tolerability of Eptinezumab

Recruiting
N/A
100
Europe
Eptinezumab 100 or 300 mg ev, Eptinezumab
University of Florence, Azienda Ospedaliero Universitaria Policlinico Modena, Società italiana per lo studio delle Cefalee (SISC), IRCCS National Neurological Institute "C. Mondino" Foundation, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Università degli Studi dell'Aquila, University of Roma La Sapienza, Euganea Health Unit, Padua, Italy, Azienda Ospedaliero-Universitaria di Parma, Azienda Ospedaliera S. Maria della Misericordia, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Cliniche Humanitas Gavazzeni, University of Campania "Luigi Vanvitelli", Ospedale di Prato, Azienda Policlinico Umberto I, Auxologico San Luca, Milano, ASST Spedali Civili, Brescia, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine
04/25
04/26
NCT06212661: Migraine Medication Effects on Urinary Symptoms

Enrolling by invitation
N/A
200
US
Ubrogepant, Ubrelvy, Rimegepant, Nurtec, Atogepant, Qulipta, Eptinezumab, Vyepti, Fremanezumab, Ajovy, Galcanezumab, Emgality, Erenumab, Aimovig, Botulinum toxin A, Botox
The Cleveland Clinic
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
05/25
05/26
EPTI-CO, NCT06446804: Follow-up of Migraine Patients on Eptinezumab

Completed
N/A
60
Europe
None, pure observationnal study
Centre Hospitalier Universitaire de Nīmes
Migraine
08/24
08/24
BEFREE, NCT06628921: The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study): a TACHIS Sub-study

Not yet recruiting
N/A
50
NA
Eptinezumab 100 or 300 mg ev, Eptinezumab
University of Florence, Società italiana per lo studio delle Cefalee (SISC), Fondazione Policlinico Universitario Campus Bio-Medico, Azienda Ospedaliero Universitaria Policlinico Modena, SISC RICe Group
Migraine
10/25
10/25
FACEpi, NCT07035197: Facilitators and Barriers to Eptinezumab Administration in Thailand

Not yet recruiting
N/A
30
RoW
Eptinezumab, Sham (No Treatment)
Chulalongkorn University, H. Lundbeck A/S
Migraine, Treatment, Treatment Refusal
07/26
07/27
EMBRACE, NCT05570149: EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.

Recruiting
N/A
500
Europe
Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution, anti CGRP monoclonal antibody
IRCCS San Raffaele Roma
Migraine Disorders
12/25
12/26
Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
2021-004404-18: Effect of antipsychotic therapy with aripiprazole long-acting on the brain structure of patients with a first episode of schizophrenia Impatto della terapia antipsicotica con aripiprazolo in formulazione a rilascio prolungato sulla struttura cerebrale dei pazienti al primo episodio di schizofrenia

Not yet recruiting
4
15
Europe
Abilify Maintena, [Aripiprazolo long-acting], Powder and solvent for prolonged-release suspension for injection, ABILIFY MAINTENA - 300 MG - POLVERE E SOLVENTE PER SOSPENSIONE A RILASCIO PROLUNGATO PER INIEZIONE - USO INTRAMUSCOLARE - FLACONCINO (VETRO) - POLVERE: 300 MG + SOLVENTE: 2 ML - 1 FLACONCINO POLVERE + 1 FLACONCINO SOLVENTE + 1 SIRINGA CON AGO + 1 SIR, ABILIFY MAINTENA - 400 MG - POLVERE E SOLVENTE PER SOSPENSIONE A RILASCIO PROLUNGATO PER INIEZIONE - USO INTRAMUSCOLARE - FLACONCINO (VETRO) - POLVERE: 400 MG + SOLVENTE: 2 ML - 1 FLACONCINO POLVERE + 1 FLACONCINO SOLVENTE + 1 SIRINGA CON AGO + 1 SIR
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO, Otsuka Pharmaceutical Italy s.r.l., Via Fabio Filzi 29, 20124 - Milano (MI)
Onset of schizophrenia Esordio di schizofrenia, Onset of symptoms of schizophrenia Prima presentazione di sintomatologia schizofrenica, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT05322031 / 2021-004404-18: The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia

Completed
4
15
Europe
Aripiprazole, Abilify Maintena, Long-acting aripiprazole
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Otsuka Pharmaceutical Italy s.r.l., Via Fabio Filzi 29, 20124 - Milano (MI)
Schizophrenia, Myelin Degeneration, Cognition Disorder
08/24
11/24
2022-001582-12: Open, multicenter, randomized clinical trial to evaluate the efficacy and safety of aripiprazole vs paliperidone / risperidone using multi-omics data in patients with a first psychotic episode. Ensayo clínico abierto, multicéntrico, aleatorizado para evaluar la eficacia y seguridad de aripiprazol vs paliperidona / risperidona mediante datos multi-ómicos en pacientes con un primer episodio psicótico.

Ongoing
4
244
Europe
Injection, Abilify Maintena, Xeplion
Consorcio Centro de Investigacion Biomedica en Red (CIBER), Instituto de Salud Carlos III
First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT05662306: C-Cog in Early Course Schizophrenia Study

Terminated
4
60
US
Aripiprazole Lauroxil, Computerized cognitive and functional skills training
University of Miami, Alkermes, Inc.
Schizophrenia
03/25
03/25
NCT03485417: Substance Misuse To Psychosis for Stimulants

Recruiting
2/3
240
RoW
Aripiprazole, Paliperidone, Treatment as Usual
The University of Hong Kong, Queen Mary Hospital, Hong Kong, North District Hospital
Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence, Stimulant Abuse, Pharmacotherapy
05/24
05/25
INITIATE, NCT04907279: Aripiprazole Once-Monthly in Hospitalized Patients

Recruiting
N/A
200
Canada
Aripiprazole Once-Monthly (AOM)
Otsuka Canada Pharmaceutical Inc., Lundbeck Canada Inc.
Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
12/22
06/23
Parkinsan (budipine) / Lundbeck, Takeda
PKT, NCT06017232: Telerehabilitation for Dysautonomia in Parkinson's Disease

Completed
N/A
16
Canada
Hybrid telerehabilitation program, OpenTera telerehabilitation
Université de Sherbrooke, Centre de Recherche sur le Vieillissement (CdRV)
Parkinson Disease
04/24
04/24
Selincro (nalmefene oral) / Lundbeck, Acorda
2016-002805-21: Evaluation du nalméfène dans les troubles du contrôle des impulsions chez des patients ayant une maladie de Parkinson

Not yet recruiting
2
30
Europe
SELINCRO, Film-coated tablet, SELINCRO
CHU Clermont-Ferrand
Patients atteints de maladie de la Parkinson idiopathique avec des troubles du contrôle des impulsions., Patients atteints de maladie de la Parkinson idiopathique avec des troubles du contrôle des impulsions., Diseases [C] - Nervous System Diseases [C10]
 
 
Circadin (melatonin prolonged release) / Lundbeck, Neurim, Flynn Pharma, Insud Pharma, Biocodex, Kuhnil Pharma
2008-006452-22: The effects of melatonin in the treatment of delirium

Ongoing
4
702
Europe
melatonin, none, Circadin, Circadin
Academic Medical Centre
Delirium in elderly patients (65 yrs and older) acutely admitted to the ward of internal medicine.
 
 
2013-005017-12: Looking into the eye of ADHD. In het oog van ADHD.

Ongoing
4
150
Europe
Ritalin, Circadin, Ritalin, Circadin, Ritalin, Circadin
Parnassia Bavo Groep - PsyQ, PsyQ The Hague
Adults with ADHD and suboptimal eye functioning. Volwassenen met ADHD en een afwijkende oogfunctie.
 
 
TXA-MELA, NCT07034560: Effectiveness of Oral Melatonin vs Oral Tranexamic Acid in the Treatment and Recurrence of Melasma

Active, not recruiting
4
75
RoW
Tranexamic Acid (TXA), melatonin (Circadin), Placebo
Thammasat University
Melasma, Treatment Outcome, Recurrence
11/25
11/25
BOMP-AID, NCT03438526: The Basel Randomized Trial

Recruiting
4
190
Europe
Melatonin (Circadin ®), Placebo, Oral tablet
University Hospital, Basel, Switzerland
Hypoactive Delirium
12/26
12/27
2004-000914-37: A DOUBLE-BLIND, PARALLEL GROUP, RANDOMISED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF CIRCADIN® 2MG IN THE IMPROVEMENT OF SLEEP QUALITY IN PATIENTS WITH INSOMNIA AGED 55-80 YEARS.

Ongoing
3
520
Europe
CIRCADIN ®, N/A,
Neurim Pharmaceuticals (1991) Ltd
Primary Insomnia in adults over 55 years
 
 
2012-002436-82: Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa Efecto de la melatonina sobre las alteraciones visuales y del sueño en enfermos afectos de Retinosis Pigmentaria

Ongoing
3
80
Europe
Circadin 2 mg, CIRCADIN 2 mg comprimidos de liberación prolongada, CIRCADIN 2 mg comprimidos de liberación prolongada
Isabel Pinilla Lozano, Ministerio de Sanidad, Política Social e Igualdad
To evaluate the sleep quality in patients with Retinitis Pigmentosa Evaluar la calidad del sueño en pacientes con RP
 
 
NCT06935292: Oral Melatonin VS Nebulized Dexmedetomidine Premedication on Attenuation of Hemodynamic Response to Direct Laryngoscopy and Tracheal Intubation in Hypertensive Patients

Not yet recruiting
2/3
70
RoW
Dexmedetomidine, Precedex, Melatonin, Circadin
Tanta University
Tracheal Intubation Morbidity, Laryngoscopy, Hemodynamic Response
04/26
04/26
2008-000281-23: Melatonin in Acute Mania Investigation (MIAMI-UK)

Ongoing
2
90
Europe
Circadin, Circadin, Circadin
University of Oxford
Bipolar Disorder (mania and hypomania)
 
 
2008-001689-97: Etude de la relation dose-effet de la mélatonine dans l\'autisme infantile.

Ongoing
2
36
Europe
circadin LP, circadin LP
CHU de Rennes
Autisme infantile, notamment les troubles du sommeil et de la communication
 
 
2012-004183-21: Melatonin for Nocturia in patients with Multiple Sclerosis

Ongoing
2
80
Europe
Circadin, N/A, Circadin, Circadin
North Bristol NHS Trust
Nocturia; Multiple Sclerosis
 
 
2012-005255-17: The effects of melatonin treatment on risk for diabetes and heart disease

Not yet recruiting
2
160
Europe
melatonin, Prolonged-release tablet, Circadin
University of Leeds, European Commission, clinical researc local network
first-degree relatives of individuals with type 2 diabetes., Diabetes is a common condition and in the majority it is due to insulin resistance. The current work investigates the role of melatonin on insulin resistance and glucose metabolism., Body processes [G] - Metabolic Phenomena [G03]
 
 
2012-001960-31: Combined drug approach to prevent liver injury during transplantation. Toediening geneesmiddelen om lever beschadiging tijdens transplantatie te verminderen. Réduction de dommage en transplantation hépatique après administration séquentielle de médicaments.

Not yet recruiting
2
82
Europe
Circadin, Flolan, Atenativ, NeoRecormon, Cetor, Vitamin E suspension, Apotransferrin, Remicade/Infliximab, Tationil 600, Cinryze, Prolonged-release tablet, Powder and solvent for solution for infusion, Solution for injection in pre-filled syringe, Powder and solvent for solution for injection, Oral suspension, Solution for infusion, Powder and solvent for concentrate for solution for infusion, Circadin, Flolan, Atenativ, NeoRecormon solution for injection in pre-filled syringe, Cetor 100E/ml poeder en oplosmiddel voor oplossing voor injectie, Vitamin E Suspension 100 mg/ml, Apotransferrin, Remicade, Tationil 600, Cinryze 500 eenheden poeder en oplosmiddel voor oplossing voor injectie
UZ Leuven, IWT-TBM
Investigation of the ischemia-reperfusion injury in patients who will undergo a liver transplantation after receiving a drug combination/multifactorial modulation beoordeling vermindering van de ischemie-reperfusie schade bij patiënten die een combinatie aan geneesmiddelen tijdens levertranplantatie hebben toegediend gekregen, Investigation of liver injury in patients who will undergo a liver transplantation after receiving a drug combination/multifactorial modulation beoordeling vermindering van leverschade bij patiënten die een een combinatie aan geneesmiddelen tijdens een levertransplantatie hebben toegediend gekregen, Body processes [G] - Biological Phenomena [G16]
 
 
2018-004048-50: Melatonin in patients with chronic pain

Not yet recruiting
2
60
Europe
Circadin, Tablet, Circadin
University of Aberdeen, NHS Grampian, , National Institute of Academic Anaesthesia
Sleep disturbance in patients with chronic pain, Sleep disturbance in patients with chronic pain, Diseases [C] - Symptoms and general pathology [C23]
 
 
NCT01628029: Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer

Active, not recruiting
2
68
US
Counseling, Counseling Intervention, Methylphenidate Hydrochloride, Concerta, Quillivant XR, Ritalin, Phototherapy, Actinotherapy, Bright Light Therapy, light therapy, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Sham Intervention, Sham Comparator, Therapeutic Melatonin, Circadin, Melatonin, Melaxen
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder
12/25
12/25
Mela-Nia, NCT06801379: A Novel Inhaled Formulation of Melatonin to Treat Adults with Insomnia: Pharmacokinetic Study

Not yet recruiting
1
5
RoW
Inhaled Melatonin (100 μg), Melatonin, N-Acetyl-5-methoxytryptamine, Oral Melatonin (4 mg), Circadin
Woolcock Institute of Medical Research
Insomnia
12/25
05/26
Mela-Nia, NCT06802913: A Novel Inhaled Formulation of Melatonin to Treat Adults with Insomnia: Efficacy Study

Not yet recruiting
1
10
RoW
Inhaled Melatonin (100 μg), Melatonin, Oral Melatonin (4 mg), N-Acetyl-5-methoxytryptamine, Circadin
Woolcock Institute of Medical Research
Insomnia
12/25
05/26
NCT06355687: Melatonin in Obese Patients in Laparoscopic Cholecystectomy

Not yet recruiting
N/A
60
NA
Melatonin, Circadin, Vitamin Supplement
Ain Shams University
Anesthesia
04/25
04/25
NCT06489327: Comparing Two Doses of Oral Melatonin as Premedication in Children Undergoing Surgery

Recruiting
N/A
120
RoW
melatonin (Circadin ®) 0.2 mg/kg, melatonin (Circadin ®) 0.4 mg/kg, placebo group
Al-Azhar University, Al-Ayen Iraqi University
Preoperative Anxiety
12/24
12/24
Trintellix (vortioxetine) / Lundbeck, Takeda
2018-004112-21: TOLERABILITY, SAFETY AND EFFICACY OF VORTIOXETINE FOR TREATMENT OF DEPRESSION IN PARKINSONIAN PATIENTS TOLLERABILITA’, SICUREZZA ED EFFICACIA DELLA VORTIOXETINA NELLA CURA DELLA DEPRESSIONE NEI PAZIENTI PARKINSONIANI

Not yet recruiting
4
20
Europe
Brintellix, [N06AX26], Oral drops, solution, BRINTELLIX - 20 MG/ML - GOCCE ORALI, SOLUZIONE - USO ORALE - FLACONE (VETRO) 15 ML - 1 FLACONE
IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL
Depression in Parkinson's disease Depressione in malattia di Parkinson, Depression in Parkinson's disease Depressione in malattia di Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT02559947: The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder

Not yet recruiting
4
50
US
Vortioxetine, Brintellix
Psychiatric Medicine Associates, L.L.C., Takeda Pharmaceuticals North America, Inc., ElMindA Ltd
Major Depressive Disorder
10/17
10/18
2017-004030-28: Changes in mental capacity and weight gain during antidepressant treatment.

Ongoing
4
320
Europe
Tablet, Brintellix
Psychiatric Research Unit, Psychiatric Research Unit
Major Depressive Disorder., Major Depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
ChiCTR1900024858: Comparison of the efficacy and safety of vortioxetine and escitalopram in depression and the corresponding changes in Brain-Gut axis

Recruiting
4
130
 
vortioxetine ;escitalopram
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang key research and development project funding: 1 million yuan (2015C03040)
Major Depressive Disorder
 
 
ChiCTR1900026697: Efficacy and safety of Vortioxetine Hydrobromide Tablets (Xin Da Yue) and Venlafaxine Hcl Sustained-Release Capsules (Yi Nuo Si) in the treatment of patients with physical symptoms of depression: a randomized controlled trial

Not yet recruiting
4
60
 
Vortioxetine Hydrobromide Tablets (Xin Da Yue) ;Venlafaxine Hcl Sustained-Release Capsules (Yi Nuo Si)
Peking University Sixth Hospital, Peking University Institute of Mental Health; Peking University Sixth Hospital, Lundbeck
Depression
 
 
VESPA, NCT03779789 / 2018-001444-66: Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Completed
4
362
Europe
Vortioxetine, Brintellix, Trintellix, Sertraline, Zoloft, citalopram, Elopram, Escitalopram, Entact, Paroxetine, Daparox, Fluoxetine, Prozac, Fluvoxamine
Azienda Ospedaliera Universitaria Integrata Verona, University of Catania
Major Depressive Disorder
02/23
02/23
Vortioxetine, NCT05481957: Adjunctive Treatment in Bipolar Depression

Completed
4
131
RoW
Vortioxetine, Brintellix®, valprote, Depakine
First Affiliated Hospital of Zhejiang University, Zhejiang University
Bipolar Depression
06/23
08/23
AVIS, NCT02357797: Adjunctive Vortioxetine in Schizophrenia

Active, not recruiting
4
88
US
Vortioxetine, Brintellix, Placebo
Northwell Health, Takeda
Schizophrenia, Negative Symptoms
10/23
06/24
VorDe-PD, NCT04301492: Tolerability, Safety and Efficacy of Vortioxetine

Recruiting
4
20
Europe
Vortioxetine
IRCCS San Raffaele Roma
Depression
07/23
07/23
NCT06805266: Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease

Not yet recruiting
4
40
NA
Vortioxetine (tablet)
Marianna Amboni
Parkinson Disease, Idiopathic, Freezing of Gait, Depression Not Otherwise Specified
12/26
02/27
VENUS, NCT05104918: Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities

Not yet recruiting
3
500
NA
Vortioxetine, VORSCOT tablets, Venlafaxine, Venlafexine
Scotmann Pharmaceuticals, Rawalpindi Medical College
Major Depressive Disorder
04/22
06/22
NCT04818099: Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy

Recruiting
3
208
RoW
Vortioxetine 10 mg, Placebo
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Brain Hospital Affiliated to Guangzhou Medical University
Radiation Injuries
10/23
04/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lu AF11167 / Lundbeck
2018-002708-15: Flexible-dose Long-term Extension Study of Lu AF11167 in Patients WithSchizophrenia With Prominent Negative Symptoms

Not yet recruiting
2
240
Europe, RoW
Lu AF11167 modified-release tablet, Modified-release tablet
H. Lundbeck A/S, H. Lundbeck A/S
schizophrenia with persistent prominent negative symptoms, schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
SCHIZO2: P1 / schizophrenia

Ongoing
1
0
RoW
Lu AF11167
Lundbeck
Schizophrenia
 
 
brexpiprazole / Generic mfg.
ACTRN12619001456145p: Does supplemental brexpiprazole affect sleep-wake and circadian parameters in youth with depressive syndromes?

Not yet recruiting
4
50
 
University of Sydney, Lundbeck Australia Pty Ltd
circadian parameters; depression
 
 
ACTRN12619001456145: Does supplemental brexpiprazole affect sleep-wake and circadian parameters in youth with depressive syndromes?

Terminated
4
50
 
University of Sydney, Lundbeck Australia Pty Ltd
circadian parameters, depression
 
 
NCT03526354: Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

Completed
4
50
US
Brexpiprazole, Study Medication, Treatment as Usual, Current Antipsychotic Treatment
University of Massachusetts, Worcester, Massachusetts General Hospital, University of North Carolina, Chapel Hill, Otsuka Pharmaceutical Co., Ltd., Augusta University
Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
02/24
02/24
NCT06580041: Precision Care for Major Depressive Disorder

Enrolling by invitation
4
150
US
Pramipexole, Methylphenidate, Phenelzine, Mindfulness-based Stress Sensitivity Therapy (MBSST), Complicated Grief Treatment (CGT), Care as usual (CAU) plan
University of California, San Francisco
Major Depressive Disorder, Depression, Depressive Disorder, Major
09/29
09/29
CAN-BIND-17, NCT05017311: Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Recruiting
4
400
Canada
Escitalopram, Cipralex, Brexpiprazole, Rexulti
Nova Scotia Health Authority, Unity Health Toronto, Centre for Addiction and Mental Health, McMaster University, Queen's University, University of Ottawa, University of British Columbia, University of Calgary, McGill University, Dalhousie University, University of Michigan, Simon Fraser University
Major Depressive Disorder
12/28
04/29
NCT03538691 / 2018-000601-22: A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Completed
3
1149
US
Brexpiprazole, OPC-34712, Rexulti, Antidepressant therapy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
07/22
07/22
2018-002783-88: A 12-week, Multicenter, Active-treatment Extension Trial to check how safe, tolerable and effective Brexpiprazole is in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type

Not yet recruiting
3
250
Europe
Brexpiprazole, OPC-34712, Film-coated tablet, REXULTI®
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation Associated With Dementia of the Alzheimer's Type, Agitation in dementia due to Alzheimer's Disease, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04162522: Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study

Completed
3
1
Canada
Escitalopram, Cipralex, Brexpiprazole, Rexulti
University Health Network, Toronto, Unity Health Toronto, Baycrest, Centre for Addiction and Mental Health, McMaster University, Queen's University, University of Ottawa, University of British Columbia, University of Calgary, McGill University, Dalhousie University, University of Michigan, Simon Fraser University
Major Depressive Disorder
12/22
12/22
NCT03198078 / 2017-001447-12: Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Completed
3
316
US
Brexpiprazole (OPC-34712), Aripiprazole, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc., H. Lundbeck A/S
Schizophrenia
04/23
04/23
NCT04258839 / 2018-004899-35: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Completed
3
95
US
Brexpiprazole, OPC-34712, LuAF41156
Otsuka Pharmaceutical Development & Commercialization, Inc., H. Lundbeck A/S
Irritability Associated With Autism Spectrum Disorder
03/23
03/23
NCT04124614: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

Completed
3
450
US
Brexpiprazole, Rexulti, Sertraline, Zoloft, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Post Traumatic Stress Disorder
07/23
08/23
NCT04174170: Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder

Completed
3
591
US
Brexpiprazole, Rexulti, Sertraline, Zoloft, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Post Traumatic Stress Disorder
07/23
08/23
2018-004899-35: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Not yet recruiting
3
95
US
Rexulti, Tablet, Rexulti
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc.
Irritability Associated With Autism Spectrum Disorder, AutismAutism Spectrum DisorderASDIrritability, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2019-000723-40: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder ( Anchor )

Not yet recruiting
3
130
US
Rexulti, Tablet, Rexulti
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc.
Irritability Associated With Autism Spectrum Disorder (ASD), AutismIrritabilityAutism Spectrum DisorderASD, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT04569448: Brexpiprazole Treatment for Bipolar I Depression

Recruiting
3
58
Canada
Brexpiprazole
Douglas Mental Health University Institute, McMaster University, Jewish General Hospital
Bipolar Depression
02/25
02/25
NCT03238326 / 2017-001459-30: Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Active, not recruiting
3
295
Europe, US, RoW
Brexpiprazole, OPC-34712
Otsuka Pharmaceutical Development & Commercialization, Inc., H. Lundbeck A/S
Schizophrenia
06/25
08/25
NCT03620981: Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Completed
2/3
410
Japan
Brexpiprazole, Placebo
Otsuka Pharmaceutical Co., Ltd.
Agitation Associated With Dementia of the Alzheimer's Type
04/23
05/23
ACTRN12623001019695: Investigating Novel Pharmacological Treatments for Anorexia Nervosa - A Clinical Trial

Recruiting
2
100
 
Monash University, Monash University
Anorexia nervosa
 
 
2019-002813-20: A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Not yet recruiting
2
240
Europe
Brexpiprazole, OPC-34712, Tablet
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc.
Borderline Personality Disorder, Borderline Personality Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT04066192: Brexpiprazole in Alcohol Use Disorder

Recruiting
2
250
US
Brexpiprazole, Placebo
University of Colorado, Denver, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder
08/25
08/25
NCT05189977: A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

Terminated
1
34
US
Propranolol, Prazosin
Otsuka Pharmaceutical Development & Commercialization, Inc., Iqvia Pty Ltd
Post-traumatic Stress Disorder (PTSD)
08/23
08/23
RAISE, NCT04641780: "Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients () - A Post Marketing Surveillance Program"

Recruiting
N/A
300
RoW
Brexpiprazole, Rexulti
Otsuka Pharmaceutical, Inc., Philippines
Schizophrenia, Major Depressive Disorder
06/23
03/24
MainRexult, NCT05169268: Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia

Recruiting
N/A
10
RoW
ARIPiprazole Injection [Abilify], Abilify Maintena, Brexpiprazole, Rexulti
The University of Hong Kong
Schizophrenia and Related Disorders, Anxiety Depression
12/24
06/25
NCT06875986: REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)

Recruiting
N/A
200
Japan
Brexpiprazole (Rexulti)
Otsuka Pharmaceutical Co., Ltd.
Alzheimer Disease
09/27
09/28
ReSD, NCT05962216: Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders

Recruiting
N/A
40
RoW
Brexpiprazole, Rexulti
Dr. Albert Kar-Kin Chung, Otsuka Pharmaceutical Co., Ltd.
Psychosis, Depression
12/25
12/25
clazakizumab (CSL300) / CSL Behring
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Recruiting
2/3
2310
Europe, Canada, Japan, US, RoW
CSL300, Clazakizumab, Placebo
CSL Behring
Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
08/29
08/29
ACTRN12624000567527: A Phase II Trial to Evaluate the Safety and Efficacy of clazakizumab for the desensitisation of highly sensitized patients on the deceased donor kidney transplant waiting list

Not yet recruiting
2
10
 
Royal Melbourne Hospital, John Perrett Bequest
End stage kidney disease
 
 
2020-002476-13: A study to look at the safety and success of using Clazakizumab in patients who have kidney disease and COVID-19.

Ongoing
2
20
Europe
Clazakizumab, N/A, Solution for injection/infusion, Clazakizumab
Imperial College London, Vitaeris Bio
Patients with kidney disease who are hospitalised with COVID-19 infection with pulmonary involvement (i.e. consistent chest imaging abnormalities) and clinical deterioration (i.e increasing oxygen requirements or biochemical signs of hyperinflammation)., Patients with kidney disease or who are immunosuppressed, who also have a diagnosis of COVID19, which affects the lungs, requiring a hospital admission., Diseases [C] - Virus Diseases [C02]
 
 
NCT04494724: Clazakizumab vs. Placebo - COVID-19 Infection

Recruiting
2
60
US
Clazakizumab, Placebo
The Methodist Hospital System
COVID-19 Infection
12/20
07/21
NCT04363502: Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

Recruiting
2
30
US
Clazakizumab, engineered humanized mAb directed against the human cytokine IL-6, Placebo
Johns Hopkins University
Covid19
05/22
05/22
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Completed
2
395
US
MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
02/25
03/25
RIGHT, NCT05727384: Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The Study

Recruiting
2
60
US
Clazakizumab, Placebo
Anne B. Newman, CSL Behring
Inflammation, Frailty
01/26
06/26
NCT03380962: Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

Active, not recruiting
1/2
20
US
Clazakizumab, Anti-IL-6 monoclonal
Stanley Jordan, MD
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
08/25
08/25
NCT03380377: Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

Completed
1/2
10
US
Clazakizumab
Stanley Jordan, MD
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
04/24
04/24
Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
ACTRN12621001616864: An evaluation of the efficacy of eptinezumab in the inpatient management of status migrainosus in comparison to intravenous lignocaine in patients who have failed other therapies

Recruiting
4
40
 
Alfred Health , Alfred Hospital
Migraine
 
 
2021-003049-40: A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Estudio con eptinezumab en participantes con migraña y cefalea por abuso de medicamentos

Not yet recruiting
4
570
Europe
VYEPTI, ALD403, Concentrate for solution for infusion, VYEPTI
H. Lundbeck A/S, H. LUNDBECK A/S, H. Lundbeck A/S
Migraine and medication overuse headache Migraña y cefalea por abuso de medicamentos, Migraine and medication overuse headache Migraña y cefalea por abuso de medicamentos, Diseases [C] - Nervous System Diseases [C10]
 
 
EVEC, NCT05284019: Real World Effectiveness of Eptinezumab in Participants With Migraine

Terminated
4
32
US
Eptinezumab, Vyepti, Erenumab, Aimovig®, Onabotulinumtoxin-A, Fremanezumab, Ajovy®, Galcanezumab, Emgality®
H. Lundbeck A/S
Migraine
02/23
04/23
NCT05452239 / 2021-003049-40: A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

Completed
4
609
Europe, US, RoW
Eptinezumab, Placebo
H. Lundbeck A/S, H. Lundbeck A/S
Migraine, Medication Overuse Headache
10/24
03/25
NCT06701526: A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

Recruiting
4
150
US
Eptinezumab
H. Lundbeck A/S
Migraine
06/26
06/26
2020-001009-22: Interventional, randomized, double-blind, parallel-group, placebocontrolled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of chronic migraine Estudio intervencionista, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de eptinezumab IV en adolescentes (12-17 años) para el tratamiento preventivo de la migraña crónica

Not yet recruiting
3
285
Europe
Eptinezumab, [NA], Concentrate for solution for infusion, Vyepti
H. Lundbeck A/S, H. LUNDBECK A/S, H. Lundbeck A/S
Migraine Migraña, Migraine Migraña, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-001649-38: Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine Estudio de extensión a largo plazo, abierto (con enmascaramiento de la dosis), de eptinezumab en niños y adolescentes con migraña crónica o episódica

Not yet recruiting
3
645
Europe
Eptinezumab, [NA], Concentrate for solution for infusion, Vyepti
H. Lundbeck A/S, H. LUNDBECK A/S, H. Lundbeck A/S
Migraine Migraña, Migraine Migraña, Diseases [C] - Nervous System Diseases [C10]
 
 
ALLEVIATE, NCT04688775 / 2020-001969-37: Eptinezumab in Participants With Episodic Cluster Headache

Completed
3
231
Europe, Japan, US, RoW
Eptinezumab, Placebo
H. Lundbeck A/S
Cluster Headache, Episodic
06/23
10/23
CHRONICLE, NCT05064397 / 2020-001968-28: A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)

Completed
3
131
Europe, US
Eptinezumab, Vyepti
H. Lundbeck A/S
Chronic Cluster Headache
06/23
06/23
PROSPECT-2, NCT04965675 / 2020-001009-22: A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Recruiting
3
285
Europe, Canada, US, RoW
Eptinezumab, Vyepti, Placebo
H. Lundbeck A/S, H. Lundbeck A/S
Chronic Migraine in Children
02/26
03/26
NCT05064371: Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

Completed
3
160
Japan
Eptinezumab
H. Lundbeck A/S
Migraine
06/24
06/24
NCT06428838: Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context

Not yet recruiting
3
102
Canada
Eptinezumab, Standard of Care
Dr George Medvedev, H. Lundbeck A/S, Centre for Neurology Studies, Surrey Neuroplasticity Clinic Inc., Royal Columbian Hospital, Surrey Memorial Hospital
Migraine, Chronic Migraine
12/25
12/25
Sunrise, NCT04921384 / 2020-001657-42: Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

Completed
3
981
Europe, Japan, RoW
Placebo, Eptinezumab, Lu AG09221
H. Lundbeck A/S, H. Lundbeck A/S
Migraine
10/24
02/25
PROSPECT-1, NCT05897320: A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Recruiting
3
315
Europe, Canada, US, RoW
Eptinezumab, Placebo
H. Lundbeck A/S
Episodic Migraine
05/27
06/27
NCT05164172 / 2020-001649-38: A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Recruiting
3
600
Europe, Canada, US, RoW
Eptinezumab, Vyepti
H. Lundbeck A/S, H. Lundbeck A/S
Migraine
09/25
03/26
NCT05937152: A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy

Withdrawn
2
100
Europe, US
Eptinezumab, Placebo
Mayo Clinic
Diabetic Polyneuropathy
11/25
11/25
NCT04537429 / 2022-004102-29: A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

Completed
1
28
US
Eptinezumab
H. Lundbeck A/S, H. Lundbeck A/S
Migraine in Children, Migraine
10/22
08/23
2022-004102-29: A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

Not yet recruiting
1
32
US
VYEPTI, Concentrate for solution for infusion, VYEPTI
H. Lundbeck A/S, H. Lundbeck A/S
Migraine in children and adolescentsMigraine, Migraine in children and young peopleMigraine, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05635604: Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.

Completed
N/A
38
Europe
Eptinezumab, PACAP-38
Danish Headache Center
Migraine
08/23
08/23
TACHIS, NCT06409845: Effectiveness and Tolerability of Eptinezumab

Recruiting
N/A
100
Europe
Eptinezumab 100 or 300 mg ev, Eptinezumab
University of Florence, Azienda Ospedaliero Universitaria Policlinico Modena, Società italiana per lo studio delle Cefalee (SISC), IRCCS National Neurological Institute "C. Mondino" Foundation, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Università degli Studi dell'Aquila, University of Roma La Sapienza, Euganea Health Unit, Padua, Italy, Azienda Ospedaliero-Universitaria di Parma, Azienda Ospedaliera S. Maria della Misericordia, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Cliniche Humanitas Gavazzeni, University of Campania "Luigi Vanvitelli", Ospedale di Prato, Azienda Policlinico Umberto I, Auxologico San Luca, Milano, ASST Spedali Civili, Brescia, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine
04/25
04/26
NCT06212661: Migraine Medication Effects on Urinary Symptoms

Enrolling by invitation
N/A
200
US
Ubrogepant, Ubrelvy, Rimegepant, Nurtec, Atogepant, Qulipta, Eptinezumab, Vyepti, Fremanezumab, Ajovy, Galcanezumab, Emgality, Erenumab, Aimovig, Botulinum toxin A, Botox
The Cleveland Clinic
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
05/25
05/26
EPTI-CO, NCT06446804: Follow-up of Migraine Patients on Eptinezumab

Completed
N/A
60
Europe
None, pure observationnal study
Centre Hospitalier Universitaire de Nīmes
Migraine
08/24
08/24
BEFREE, NCT06628921: The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study): a TACHIS Sub-study

Not yet recruiting
N/A
50
NA
Eptinezumab 100 or 300 mg ev, Eptinezumab
University of Florence, Società italiana per lo studio delle Cefalee (SISC), Fondazione Policlinico Universitario Campus Bio-Medico, Azienda Ospedaliero Universitaria Policlinico Modena, SISC RICe Group
Migraine
10/25
10/25
FACEpi, NCT07035197: Facilitators and Barriers to Eptinezumab Administration in Thailand

Not yet recruiting
N/A
30
RoW
Eptinezumab, Sham (No Treatment)
Chulalongkorn University, H. Lundbeck A/S
Migraine, Treatment, Treatment Refusal
07/26
07/27
EMBRACE, NCT05570149: EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.

Recruiting
N/A
500
Europe
Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution, anti CGRP monoclonal antibody
IRCCS San Raffaele Roma
Migraine Disorders
12/25
12/26
Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
2021-004404-18: Effect of antipsychotic therapy with aripiprazole long-acting on the brain structure of patients with a first episode of schizophrenia Impatto della terapia antipsicotica con aripiprazolo in formulazione a rilascio prolungato sulla struttura cerebrale dei pazienti al primo episodio di schizofrenia

Not yet recruiting
4
15
Europe
Abilify Maintena, [Aripiprazolo long-acting], Powder and solvent for prolonged-release suspension for injection, ABILIFY MAINTENA - 300 MG - POLVERE E SOLVENTE PER SOSPENSIONE A RILASCIO PROLUNGATO PER INIEZIONE - USO INTRAMUSCOLARE - FLACONCINO (VETRO) - POLVERE: 300 MG + SOLVENTE: 2 ML - 1 FLACONCINO POLVERE + 1 FLACONCINO SOLVENTE + 1 SIRINGA CON AGO + 1 SIR, ABILIFY MAINTENA - 400 MG - POLVERE E SOLVENTE PER SOSPENSIONE A RILASCIO PROLUNGATO PER INIEZIONE - USO INTRAMUSCOLARE - FLACONCINO (VETRO) - POLVERE: 400 MG + SOLVENTE: 2 ML - 1 FLACONCINO POLVERE + 1 FLACONCINO SOLVENTE + 1 SIRINGA CON AGO + 1 SIR
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO, Otsuka Pharmaceutical Italy s.r.l., Via Fabio Filzi 29, 20124 - Milano (MI)
Onset of schizophrenia Esordio di schizofrenia, Onset of symptoms of schizophrenia Prima presentazione di sintomatologia schizofrenica, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT05322031 / 2021-004404-18: The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia

Completed
4
15
Europe
Aripiprazole, Abilify Maintena, Long-acting aripiprazole
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Otsuka Pharmaceutical Italy s.r.l., Via Fabio Filzi 29, 20124 - Milano (MI)
Schizophrenia, Myelin Degeneration, Cognition Disorder
08/24
11/24
2022-001582-12: Open, multicenter, randomized clinical trial to evaluate the efficacy and safety of aripiprazole vs paliperidone / risperidone using multi-omics data in patients with a first psychotic episode. Ensayo clínico abierto, multicéntrico, aleatorizado para evaluar la eficacia y seguridad de aripiprazol vs paliperidona / risperidona mediante datos multi-ómicos en pacientes con un primer episodio psicótico.

Ongoing
4
244
Europe
Injection, Abilify Maintena, Xeplion
Consorcio Centro de Investigacion Biomedica en Red (CIBER), Instituto de Salud Carlos III
First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT05662306: C-Cog in Early Course Schizophrenia Study

Terminated
4
60
US
Aripiprazole Lauroxil, Computerized cognitive and functional skills training
University of Miami, Alkermes, Inc.
Schizophrenia
03/25
03/25
NCT03485417: Substance Misuse To Psychosis for Stimulants

Recruiting
2/3
240
RoW
Aripiprazole, Paliperidone, Treatment as Usual
The University of Hong Kong, Queen Mary Hospital, Hong Kong, North District Hospital
Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence, Stimulant Abuse, Pharmacotherapy
05/24
05/25
INITIATE, NCT04907279: Aripiprazole Once-Monthly in Hospitalized Patients

Recruiting
N/A
200
Canada
Aripiprazole Once-Monthly (AOM)
Otsuka Canada Pharmaceutical Inc., Lundbeck Canada Inc.
Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
12/22
06/23
Parkinsan (budipine) / Lundbeck, Takeda
PKT, NCT06017232: Telerehabilitation for Dysautonomia in Parkinson's Disease

Completed
N/A
16
Canada
Hybrid telerehabilitation program, OpenTera telerehabilitation
Université de Sherbrooke, Centre de Recherche sur le Vieillissement (CdRV)
Parkinson Disease
04/24
04/24
Selincro (nalmefene oral) / Lundbeck, Acorda
2016-002805-21: Evaluation du nalméfène dans les troubles du contrôle des impulsions chez des patients ayant une maladie de Parkinson

Not yet recruiting
2
30
Europe
SELINCRO, Film-coated tablet, SELINCRO
CHU Clermont-Ferrand
Patients atteints de maladie de la Parkinson idiopathique avec des troubles du contrôle des impulsions., Patients atteints de maladie de la Parkinson idiopathique avec des troubles du contrôle des impulsions., Diseases [C] - Nervous System Diseases [C10]
 
 
Circadin (melatonin prolonged release) / Lundbeck, Neurim, Flynn Pharma, Insud Pharma, Biocodex, Kuhnil Pharma
2008-006452-22: The effects of melatonin in the treatment of delirium

Ongoing
4
702
Europe
melatonin, none, Circadin, Circadin
Academic Medical Centre
Delirium in elderly patients (65 yrs and older) acutely admitted to the ward of internal medicine.
 
 
2013-005017-12: Looking into the eye of ADHD. In het oog van ADHD.

Ongoing
4
150
Europe
Ritalin, Circadin, Ritalin, Circadin, Ritalin, Circadin
Parnassia Bavo Groep - PsyQ, PsyQ The Hague
Adults with ADHD and suboptimal eye functioning. Volwassenen met ADHD en een afwijkende oogfunctie.
 
 
TXA-MELA, NCT07034560: Effectiveness of Oral Melatonin vs Oral Tranexamic Acid in the Treatment and Recurrence of Melasma

Active, not recruiting
4
75
RoW
Tranexamic Acid (TXA), melatonin (Circadin), Placebo
Thammasat University
Melasma, Treatment Outcome, Recurrence
11/25
11/25
BOMP-AID, NCT03438526: The Basel Randomized Trial

Recruiting
4
190
Europe
Melatonin (Circadin ®), Placebo, Oral tablet
University Hospital, Basel, Switzerland
Hypoactive Delirium
12/26
12/27
2004-000914-37: A DOUBLE-BLIND, PARALLEL GROUP, RANDOMISED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF CIRCADIN® 2MG IN THE IMPROVEMENT OF SLEEP QUALITY IN PATIENTS WITH INSOMNIA AGED 55-80 YEARS.

Ongoing
3
520
Europe
CIRCADIN ®, N/A,
Neurim Pharmaceuticals (1991) Ltd
Primary Insomnia in adults over 55 years
 
 
2012-002436-82: Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa Efecto de la melatonina sobre las alteraciones visuales y del sueño en enfermos afectos de Retinosis Pigmentaria

Ongoing
3
80
Europe
Circadin 2 mg, CIRCADIN 2 mg comprimidos de liberación prolongada, CIRCADIN 2 mg comprimidos de liberación prolongada
Isabel Pinilla Lozano, Ministerio de Sanidad, Política Social e Igualdad
To evaluate the sleep quality in patients with Retinitis Pigmentosa Evaluar la calidad del sueño en pacientes con RP
 
 
NCT06935292: Oral Melatonin VS Nebulized Dexmedetomidine Premedication on Attenuation of Hemodynamic Response to Direct Laryngoscopy and Tracheal Intubation in Hypertensive Patients

Not yet recruiting
2/3
70
RoW
Dexmedetomidine, Precedex, Melatonin, Circadin
Tanta University
Tracheal Intubation Morbidity, Laryngoscopy, Hemodynamic Response
04/26
04/26
2008-000281-23: Melatonin in Acute Mania Investigation (MIAMI-UK)

Ongoing
2
90
Europe
Circadin, Circadin, Circadin
University of Oxford
Bipolar Disorder (mania and hypomania)
 
 
2008-001689-97: Etude de la relation dose-effet de la mélatonine dans l\'autisme infantile.

Ongoing
2
36
Europe
circadin LP, circadin LP
CHU de Rennes
Autisme infantile, notamment les troubles du sommeil et de la communication
 
 
2012-004183-21: Melatonin for Nocturia in patients with Multiple Sclerosis

Ongoing
2
80
Europe
Circadin, N/A, Circadin, Circadin
North Bristol NHS Trust
Nocturia; Multiple Sclerosis
 
 
2012-005255-17: The effects of melatonin treatment on risk for diabetes and heart disease

Not yet recruiting
2
160
Europe
melatonin, Prolonged-release tablet, Circadin
University of Leeds, European Commission, clinical researc local network
first-degree relatives of individuals with type 2 diabetes., Diabetes is a common condition and in the majority it is due to insulin resistance. The current work investigates the role of melatonin on insulin resistance and glucose metabolism., Body processes [G] - Metabolic Phenomena [G03]
 
 
2012-001960-31: Combined drug approach to prevent liver injury during transplantation. Toediening geneesmiddelen om lever beschadiging tijdens transplantatie te verminderen. Réduction de dommage en transplantation hépatique après administration séquentielle de médicaments.

Not yet recruiting
2
82
Europe
Circadin, Flolan, Atenativ, NeoRecormon, Cetor, Vitamin E suspension, Apotransferrin, Remicade/Infliximab, Tationil 600, Cinryze, Prolonged-release tablet, Powder and solvent for solution for infusion, Solution for injection in pre-filled syringe, Powder and solvent for solution for injection, Oral suspension, Solution for infusion, Powder and solvent for concentrate for solution for infusion, Circadin, Flolan, Atenativ, NeoRecormon solution for injection in pre-filled syringe, Cetor 100E/ml poeder en oplosmiddel voor oplossing voor injectie, Vitamin E Suspension 100 mg/ml, Apotransferrin, Remicade, Tationil 600, Cinryze 500 eenheden poeder en oplosmiddel voor oplossing voor injectie
UZ Leuven, IWT-TBM
Investigation of the ischemia-reperfusion injury in patients who will undergo a liver transplantation after receiving a drug combination/multifactorial modulation beoordeling vermindering van de ischemie-reperfusie schade bij patiënten die een combinatie aan geneesmiddelen tijdens levertranplantatie hebben toegediend gekregen, Investigation of liver injury in patients who will undergo a liver transplantation after receiving a drug combination/multifactorial modulation beoordeling vermindering van leverschade bij patiënten die een een combinatie aan geneesmiddelen tijdens een levertransplantatie hebben toegediend gekregen, Body processes [G] - Biological Phenomena [G16]
 
 
2018-004048-50: Melatonin in patients with chronic pain

Not yet recruiting
2
60
Europe
Circadin, Tablet, Circadin
University of Aberdeen, NHS Grampian, , National Institute of Academic Anaesthesia
Sleep disturbance in patients with chronic pain, Sleep disturbance in patients with chronic pain, Diseases [C] - Symptoms and general pathology [C23]
 
 
NCT01628029: Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer

Active, not recruiting
2
68
US
Counseling, Counseling Intervention, Methylphenidate Hydrochloride, Concerta, Quillivant XR, Ritalin, Phototherapy, Actinotherapy, Bright Light Therapy, light therapy, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Sham Intervention, Sham Comparator, Therapeutic Melatonin, Circadin, Melatonin, Melaxen
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder
12/25
12/25
Mela-Nia, NCT06801379: A Novel Inhaled Formulation of Melatonin to Treat Adults with Insomnia: Pharmacokinetic Study

Not yet recruiting
1
5
RoW
Inhaled Melatonin (100 μg), Melatonin, N-Acetyl-5-methoxytryptamine, Oral Melatonin (4 mg), Circadin
Woolcock Institute of Medical Research
Insomnia
12/25
05/26
Mela-Nia, NCT06802913: A Novel Inhaled Formulation of Melatonin to Treat Adults with Insomnia: Efficacy Study

Not yet recruiting
1
10
RoW
Inhaled Melatonin (100 μg), Melatonin, Oral Melatonin (4 mg), N-Acetyl-5-methoxytryptamine, Circadin
Woolcock Institute of Medical Research
Insomnia
12/25
05/26
NCT06355687: Melatonin in Obese Patients in Laparoscopic Cholecystectomy

Not yet recruiting
N/A
60
NA
Melatonin, Circadin, Vitamin Supplement
Ain Shams University
Anesthesia
04/25
04/25
NCT06489327: Comparing Two Doses of Oral Melatonin as Premedication in Children Undergoing Surgery

Recruiting
N/A
120
RoW
melatonin (Circadin ®) 0.2 mg/kg, melatonin (Circadin ®) 0.4 mg/kg, placebo group
Al-Azhar University, Al-Ayen Iraqi University
Preoperative Anxiety
12/24
12/24
Trintellix (vortioxetine) / Lundbeck, Takeda
2018-004112-21: TOLERABILITY, SAFETY AND EFFICACY OF VORTIOXETINE FOR TREATMENT OF DEPRESSION IN PARKINSONIAN PATIENTS TOLLERABILITA’, SICUREZZA ED EFFICACIA DELLA VORTIOXETINA NELLA CURA DELLA DEPRESSIONE NEI PAZIENTI PARKINSONIANI

Not yet recruiting
4
20
Europe
Brintellix, [N06AX26], Oral drops, solution, BRINTELLIX - 20 MG/ML - GOCCE ORALI, SOLUZIONE - USO ORALE - FLACONE (VETRO) 15 ML - 1 FLACONE
IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL
Depression in Parkinson's disease Depressione in malattia di Parkinson, Depression in Parkinson's disease Depressione in malattia di Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT02559947: The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder

Not yet recruiting
4
50
US
Vortioxetine, Brintellix
Psychiatric Medicine Associates, L.L.C., Takeda Pharmaceuticals North America, Inc., ElMindA Ltd
Major Depressive Disorder
10/17
10/18
2017-004030-28: Changes in mental capacity and weight gain during antidepressant treatment.

Ongoing
4
320
Europe
Tablet, Brintellix
Psychiatric Research Unit, Psychiatric Research Unit
Major Depressive Disorder., Major Depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
ChiCTR1900024858: Comparison of the efficacy and safety of vortioxetine and escitalopram in depression and the corresponding changes in Brain-Gut axis

Recruiting
4
130
 
vortioxetine ;escitalopram
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang key research and development project funding: 1 million yuan (2015C03040)
Major Depressive Disorder
 
 
ChiCTR1900026697: Efficacy and safety of Vortioxetine Hydrobromide Tablets (Xin Da Yue) and Venlafaxine Hcl Sustained-Release Capsules (Yi Nuo Si) in the treatment of patients with physical symptoms of depression: a randomized controlled trial

Not yet recruiting
4
60
 
Vortioxetine Hydrobromide Tablets (Xin Da Yue) ;Venlafaxine Hcl Sustained-Release Capsules (Yi Nuo Si)
Peking University Sixth Hospital, Peking University Institute of Mental Health; Peking University Sixth Hospital, Lundbeck
Depression
 
 
VESPA, NCT03779789 / 2018-001444-66: Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Completed
4
362
Europe
Vortioxetine, Brintellix, Trintellix, Sertraline, Zoloft, citalopram, Elopram, Escitalopram, Entact, Paroxetine, Daparox, Fluoxetine, Prozac, Fluvoxamine
Azienda Ospedaliera Universitaria Integrata Verona, University of Catania
Major Depressive Disorder
02/23
02/23
Vortioxetine, NCT05481957: Adjunctive Treatment in Bipolar Depression

Completed
4
131
RoW
Vortioxetine, Brintellix®, valprote, Depakine
First Affiliated Hospital of Zhejiang University, Zhejiang University
Bipolar Depression
06/23
08/23
AVIS, NCT02357797: Adjunctive Vortioxetine in Schizophrenia

Active, not recruiting
4
88
US
Vortioxetine, Brintellix, Placebo
Northwell Health, Takeda
Schizophrenia, Negative Symptoms
10/23
06/24
VorDe-PD, NCT04301492: Tolerability, Safety and Efficacy of Vortioxetine

Recruiting
4
20
Europe
Vortioxetine
IRCCS San Raffaele Roma
Depression
07/23
07/23
NCT06805266: Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease

Not yet recruiting
4
40
NA
Vortioxetine (tablet)
Marianna Amboni
Parkinson Disease, Idiopathic, Freezing of Gait, Depression Not Otherwise Specified
12/26
02/27
VENUS, NCT05104918: Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities

Not yet recruiting
3
500
NA
Vortioxetine, VORSCOT tablets, Venlafaxine, Venlafexine
Scotmann Pharmaceuticals, Rawalpindi Medical College
Major Depressive Disorder
04/22
06/22
NCT04818099: Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy

Recruiting
3
208
RoW
Vortioxetine 10 mg, Placebo
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Brain Hospital Affiliated to Guangzhou Medical University
Radiation Injuries
10/23
04/24
 

Download Options